Refine
Year of publication
Document Type
- Article (218)
- Preprint (92)
- Conference Proceeding (4)
- Book (2)
- Review (2)
Language
- English (303)
- German (14)
- Multiple languages (1)
Has Fulltext
- yes (318)
Is part of the Bibliography
- no (318)
Keywords
- BESIII (9)
- Branching fraction (7)
- e +-e − Experiments (7)
- Lepton colliders (4)
- Particle and Resonance Production (4)
- Charm Physics (3)
- Charmed mesons (3)
- Electroweak interaction (3)
- Hadronic decays (3)
- e+-e− Experiments (3)
- Biomarkers (2)
- Branching fractions (2)
- CV9202 (2)
- Charm physics (2)
- Consensus (2)
- Diagnostik (2)
- Electroweak Interaction (2)
- Exotics (2)
- Früherkennung (2)
- Leptonic, semileptonic & radiative decays (2)
- MRI (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Non-small cell lung cancer (2)
- Oncology (2)
- Particle decays (2)
- Polarization (2)
- Quarkonium (2)
- Rehabilitation (2)
- Richtlinie (2)
- SARS-CoV-2 (2)
- Spectroscopy (2)
- breast cancer (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- screening (2)
- ACL (1)
- ATM (1)
- Actin (1)
- Active middle ear implants (1)
- Activities of daily living (1)
- Acute inflammation (1)
- Acute myeloid leukemia (1)
- Alzheimer's disease (1)
- Animal models (1)
- Antiretroviral therapy (1)
- Antiretrovirals (1)
- Antirheumatic agents (1)
- Archaeogeophysics (1)
- Ascites (1)
- Auditory system (1)
- Austria (1)
- Automata theory (1)
- B cell receptor (1)
- BESIII detector (1)
- BI1361849 (1)
- BPDCN (1)
- Berci needle (1)
- Bevacizumab (1)
- Bhabha (1)
- Bone conduction devices (1)
- Born cross section measurement (1)
- BrainNet Europe consortium (1)
- Business strategy in drug development (1)
- Bypass liner (1)
- C1-INH (C1 inhibitor, C1-esterase inhibitor) (1)
- CAKUT (1)
- CDKN2A (1)
- COVID-19 (1)
- CP violation (1)
- CRISPR/Cas (1)
- Cancer (1)
- Capecitabine (1)
- Cardiomyopathy (1)
- Carex firma community (1)
- Carex sempervirens community (1)
- Caricion davallianae (1)
- Charmonia (1)
- Charmonium (1)
- Charmonium (-like) (1)
- Cherenkov counter: lead-glass (1)
- Child (1)
- Chondral Lesion (1)
- Cirrhosis (1)
- Claudin 5 (1)
- Clinical trial (1)
- Cognitive impairment (1)
- Cohort studies (1)
- Comparative effectiveness research (1)
- Complex I (1)
- Consensus statement (1)
- Covid-19 (1)
- Cross section (1)
- D meson (1)
- Dark photon (1)
- Dark sector (1)
- Dermatomyositis (1)
- Diabetes (1)
- Diagnosis (1)
- Diagnostic differentiation (1)
- Diagnostic markers (1)
- Dilated cardiomyopathy (1)
- Direct oral anticoagulation (1)
- Drug screens (1)
- Drug therapy (1)
- Dumon stents (1)
- Electromagnetic form factor (1)
- Electromagnetic form factors (1)
- Electron-pion identification (1)
- Endoscopy (1)
- Esophageal adenocarcinoma (1)
- Exercise (1)
- Experimental nuclear physics (1)
- Experimental particle physics (1)
- FAPI PET (1)
- FOS: Physical sciences (1)
- Fagus sylvatica (1)
- Festuco-Brometea (1)
- Fibre/foam sandwich radiator (1)
- Flavor changing neutral currents (1)
- Flavor symmetries (1)
- Flavour Physics (1)
- Form factors (1)
- Full waveform (1)
- Function (1)
- Gadobutrol (1)
- Gadopentate dimeglumine (1)
- Genome editing (1)
- Glioblastoma survival (1)
- HADES (1)
- HIV (1)
- HIV-1 (1)
- Haploidentical stem cell transplantation (1)
- Harz Mountains foothills (1)
- Health policy (1)
- Heart (1)
- Heart transplantation (1)
- Heavy ion storage ring (1)
- Hematology (1)
- Hepatitis C virus (1)
- Hereditary angioedema (1)
- High Energy Physics - Experiment (hep-ex) (1)
- Hsp70 (1)
- Hyperons (1)
- Hypofractionated radiotherapy (1)
- IHC (1)
- Immunomonitoring (1)
- Infinite games with perfect information (1)
- Initial state radiation (1)
- Interpretation (1)
- Intragastric balloon (1)
- Inversion (1)
- Invisible decays (1)
- Ionisation energy loss (1)
- KIR (1)
- KRAS (1)
- Lactic acidosis (1)
- Leukemias (1)
- Liver diseases (1)
- Liver transplantation (1)
- Low-molecular-weight heparin (1)
- MEDIC (1)
- MLL (1)
- Mena/VASP (1)
- Minimal residual disease (1)
- Mitochondrial disorder (1)
- Mixed hearing loss (1)
- Molecular diagnostic testing (1)
- Molinio-Arrhenatheretea (1)
- Multi-stakeholder approach (1)
- Multi-wire proportional drift chamber (1)
- NK cells (1)
- NMDA IgA/IgM antibodies (1)
- NMDA antibody (1)
- NRAS (1)
- Neonatal (1)
- Neural network (1)
- Neutrinos (1)
- Noninferiority (1)
- Obesity (1)
- Orbital electron capture (1)
- Ovarian cancer (1)
- Oxaliplatin (1)
- PDE‐5‐inhibitor (1)
- Parkinson disease (1)
- Particle and resonance production (1)
- Particle phenomena (1)
- Patellofemoral Joint (1)
- Pediatric (1)
- Physiotherapy (1)
- Preoperative radiochemotherapy (1)
- Prognosis (1)
- Proton (1)
- Pulmonary embolism (1)
- QCD (1)
- Quantum chromodynamics (1)
- RHIC (1)
- RNActive (1)
- Radiative decay (1)
- Rare decays (1)
- Rectal cancer (1)
- Registries (1)
- Renal lesions (1)
- Renal replacement therapy (1)
- Respiration (1)
- SCCHN (1)
- SLC20A1 (1)
- STAR (1)
- STIR (1)
- Semi-leptonic decays (1)
- Single particle decay spectroscopy (1)
- Single-leg hop for distance (1)
- Spectrin (1)
- Spin alignment (1)
- Surgery (1)
- TILs (1)
- TLR2/6 (1)
- TR (1)
- Technical data (1)
- Techniques Electromagnetic calorimeters (1)
- Therapeutic anticoagulation (1)
- Tomography (1)
- Tracking (1)
- Transition radiation detector (1)
- Treatment (1)
- Trigger (1)
- Two body weak decay (1)
- VE-cadherin (1)
- VEGF (1)
- VISTA (1)
- Validity (1)
- Vascular permeability (1)
- Violion caninae (1)
- Vitamin (1)
- Weight loss (1)
- Xenon-based gas mixture (1)
- Y states (1)
- acute myeloid leukemia (1)
- adult and elderly patients (1)
- aegean (1)
- airway (1)
- algorithms (1)
- alpine vegetation (1)
- angiogenesis (1)
- annual bleeding rate (1)
- arteriogenesis (1)
- artifacts (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- auditory system (1)
- beech forests (1)
- bladder exstrophy-epispadias complex (1)
- blastic plasmacytoid dendritic cell neoplasm (1)
- blood flow recovery (1)
- bone-marrow (1)
- calorimeter: electromagnetic (1)
- center-of-mass energy (1)
- cerebral sinus and vein thrombosis (CVT) (1)
- charmonium-like states (1)
- cisplatin (1)
- cloacal malformation (1)
- coastal geomorphology (1)
- cohlear implant (1)
- collateral growth (1)
- combinatorics (1)
- comorbidity (1)
- component study (1)
- cone-beam computed tomography (CBCT) (1)
- cone-beam computer tomography (1)
- coronary artery disease (1)
- cytarabine dose (1)
- dE/dx (1)
- data quality (1)
- data structures (1)
- decompressive craniectomy (1)
- denervation (1)
- dimuon (1)
- dynamic vegetation model (1)
- e+e − annihilation (1)
- e+e⁻ − Experiments (1)
- e+e− Experiments (1)
- early tumor stages (1)
- effectiveness (1)
- elderly (1)
- electric and acustic stymulation (1)
- electrical resistivity tomography (1)
- electroencephalography (EEG) (1)
- electromagnetic navigation bronchoscopy (EMN, ENB) (1)
- electron-positron collision (1)
- electronics: readout (1)
- endothelial function (1)
- erectile dysfunction (1)
- femoral artery ligation (1)
- fibre: optical (1)
- fibrosis imaging (1)
- fluid shear stress (1)
- foraminifera (1)
- functional genetics (1)
- geophysical prospections (1)
- global warming (1)
- hadron spectroscopy (1)
- hadronic events (1)
- haemophilia A (1)
- hearing loss (1)
- helicity amplitude analysis (1)
- hierarchies and reducibilities (1)
- immunohistochemistry (1)
- inclusive J/ψ decays (1)
- inner ear (1)
- intracerebral hemorrhage (ICH) (1)
- intratumoral (1)
- kidney formation (1)
- lipiodol (1)
- local radiotherapy (1)
- logic (1)
- lung cancer (1)
- mRNA active cancer immunotherapy (1)
- mRNA vaccine (1)
- magnetic gradiometry (1)
- micropalaeontology (1)
- microwave ablation (1)
- mindfulness (1)
- monocytes (1)
- multicenter study (1)
- mutually exclusive mutations (1)
- mycorrhiza (1)
- nanoparticle (1)
- natural reforestation (1)
- neurofibrillary pathology (1)
- neuropathological diagnosis (1)
- neutralizing antibodies (1)
- next generation sequencing (1)
- nitrogen deposition (1)
- non-small cell lung cancer (1)
- non‐selective beta‐blocker (1)
- nuclear cardiology (1)
- number of J/ψ events (1)
- nutrient cycling (1)
- permanent plots (1)
- plant community assembly (1)
- plant functional traits (1)
- plant succession (1)
- plasma-derived factor VIII concentrate, prophylaxis (1)
- portal hypertension (1)
- prognosis (1)
- prognostic biomarker (1)
- psychotherapy process (1)
- pulmonary hypertension (1)
- radiation (1)
- randomized controlled trial (RCT) (1)
- reactive systems (1)
- recurrent mutations (1)
- retrospective trial (1)
- rolipram (1)
- solitary pulmonary nodule (1)
- species composition (1)
- species richness (1)
- specification and verification (1)
- spike protein (1)
- spiral ganglion cell (1)
- stability (1)
- stent (1)
- succession (1)
- tetraquark (1)
- therapeutic alliance (1)
- tracheobronchomalacia (1)
- transbronchial biopsy (TBB) (1)
- trigger efficiency (1)
- tropical montane forests (TMF) (1)
- urinary tract development (1)
- vaccination (1)
- vaccine-induced immune thrombotic thrombocytopenia (VITT) (1)
- variants of concern (1)
- vegetation classification (1)
- verification (1)
- von Willebrand disease (1)
- windthrow (1)
- zebrafish development (1)
- Λ+c baryon (1)
- Σ hyperon (1)
Institute
In den Jahren 1998-2001 wurden im südwestlichen Harzvorland in Windwurfgebieten auf Unterem Buntsandstein vegetationsökologische und gehölzkundliche Erhebungen auf Dauerflächen durchgeführt, um die Sukzessionsdynamik und Regeneration gestörter Buchenwälder (Galio odorati-Fagetum, Luzulo-Fagetum) in Abhängigkeit von ehemaliger Nutzungsgeschichte, aktueller forstlicher (Nicht-) Behandlung und Störungsflächengröße zu studieren. Im vierten Jahr nach dem 1997er Sturm wird das Bild in allen großflächig geworfenen Bestandesteilen durch ausgedehnte Pionierstrauchfluren bestimmt (hauptsächlich Rubus idaeus, ferner auch Sambucus racemosa, S. nigra und Rubus fruticosus agg.), während Pionierbaumarten weitestgehend fehlen. In allen Untersuchungsflächen steigen die Artenzahlen bis zum vierten Jahr nach dem Sturm an. Unter der üppig entwickelten Strauchschicht ist ein Überdauern laubwaldtypischer Querco-Fagetea-Arten und damit von Frische- und Schattenzeigern zu beobachten und auch in Zukunft wahrscheinlich. Ruderalfluren (v.a. mit Artemisietea-Arten) stellten nur ein kurzfristiges Zwischenstadium dar. Obwohl sich die Flächen im bisherigen Sukzessionsverlauf angleichen, sind anfangs noch deutliche Unterschiede zwischen dem etwa 30 Jahre ungenutzten Naturwald Königsbuche und den bewirtschafteten Wäldern ersichtlich. Dies zeigt sich beim Naturwald u.a. in relativ geringen Artenzahlen sowie geringen Abundanzanteilen an Epilobietea-Arten, Sträuchern, Licht- und Stickstoffzeigern. Damit bestätigen sich Erkenntnisse aus Vergleichsuntersuchungen von nicht geworfenen Natur- und Wirtschaftswäldern in der Optimalphase. Im Unterschied zu geräumten Flächen zeichnen sich belassene Flächen u.a. durch eine geringere Artenzahl sowie vergleichsweise hohe Abundanzanteile an Krautigen und Arten mit temporärer bis kurzfristiger Samenbank aus. Die Störungsflächengröße hat ebenfalls einen großen Einfluss auf den Sukzessionsverlauf. Mit zunehmender Ausdehnung der gestörten Fläche und abnehmender Überschirmung steigt die Artenzahl immer stärker an. Gleichzeitig wird eine Veränderung hin zu waldfremden Sukzessionstadien deutlicher. Die Klimaxbaumart Buche behält in der Naturverjüngung zwar die Dominanz, verliert mit zunehmender Störungsflächengröße aber Anteile am Baumartenspektrum und weist stark sinkende Sämlingszahlen auf, vermutlich bedingt durch die Konkurrenz der Pionierstrauchfluren. Während in Windwurflücken die Waldregeneration hin zur standortstypischen Buchenwaldgesellschaft unmittelbar gewährleistet ist, wird sie bei Flächenwurf längere Zeit in Anspruch nehmen. Hierin besteht ein wesentlicher Unterschied zu benachbarten Buchen-Windwürfen auf basenreichen Standorten (z.B. Hainholz bei Osterode), wo die Waldregeneration unabhängig von der Störungsflächengröße ohne Pionierstadien sehr schnell voranschreitet. Dies könnte in zukünftigen Waldbaukonzepten für vergleichbare Windwurfsituationen berücksichtigt werden, indem eine Wiederaufforstung nur noch bei entsprechend ungünstigen Verjüngungsvorräten notwendig wird. Es finden sich bisher keine Hinweise auf einen Artenwechsel, wie er z.B. von REMMERT (1985, 1987, 1991) im Mosaik-Zyklus-Konzept postuliert wurde. Eher sollte von einer zwischenzeitlichen Überlagerung der ursprünglichen Vegetation gesprochen werden, die von Standort und Störungsflächengröße abhängig ist und eine teilweise massive Verschiebung in den Dominanzverhältnissen der Waldarten mit einschliesst.
Cardiovascular diseases account for more than half of total mortality before the age of 75 in industrialized countries. To develop therapies promoting the compensatory growth of blood vessels could be superior to palliative surgical surgical interventions. Therefore, much effort has been put into investigating underlying mechanisms. Depending on the initial trigger, growth of blood vessels in adult organisms proceeds via two major processes, angiogenesis and arteriogenesis. While angiogenesis is induced by hypoxia and results in new capillaries, arteriogenesis is induced by physical forces, most importantly fluid shear stress. Consequently, chronically elevated fluid shear stress was found to be the strongest trigger under experimental conditions. Arteriogenesis describes the remodelling of pre-existing arterio-arteriolar anastomoses to completely developed and functional arteries. In both growth processes, enlargement of vascular wall structures was proposed to be covered by proliferation of existing wall cells. Recently, increasing evidence emerges, implicating a pivotal role for circulating cells, above all blood monocytes, in vascular growth processes. Since it has been shown that monocytes/macrophage release a cocktail of chemokines, growth factors and proteases involved in vascular growth, their contribution seems to be of a paracrine fashion. A similar role is currently discussed for various populations of bone-marrow derived stem cells and endothelial progenitors. In contrast, the initial hypothesis that these cells -after undergoing a (trans-)differentiation- contribute by a structural integration into the growing vessel wall, is increasingly challenged.
Beyond their role in pathogen recognition and the initiation of immune defense, Toll-like receptors (TLRs) are known to be involved in various vascular processes in health and disease. We investigated the potential of the lipopeptide and TLR2/6 ligand macrophage activating protein of 2-kDA (MALP-2) to promote blood flow recovery in mice. Hypercholesterolemic apolipoprotein E (Apoe)-deficient mice were subjected to microsurgical ligation of the femoral artery. MALP-2 significantly improved blood flow recovery at early time points (three and seven days), as assessed by repeated laser speckle imaging, and increased the growth of pre-existing collateral arteries in the upper hind limb, along with intimal endothelial cell proliferation in the collateral wall and pericollateral macrophage accumulation. In addition, MALP-2 increased capillary density in the lower hind limb. MALP-2 enhanced endothelial nitric oxide synthase (eNOS) phosphorylation and nitric oxide (NO) release from endothelial cells and improved the experimental vasorelaxation of mesenteric arteries ex vivo. In vitro, MALP-2 led to the up-regulated expression of major endothelial adhesion molecules as well as their leukocyte integrin receptors and consequently enhanced the endothelial adhesion of leukocytes. Using the experimental approach of femoral artery ligation (FAL), we achieved promising results with MALP-2 to promote peripheral blood flow recovery by collateral artery growth.
BACKGROUND: In the heart, cytoplasmic actin networks are thought to have important roles in mechanical support, myofibrillogenesis, and ion channel function. However, subcellular localization of cytoplasmic actin isoforms and proteins involved in the modulation of the cytoplasmic actin networks are elusive. Mena and VASP are important regulators of actin dynamics. Due to the lethal phenotype of mice with combined deficiency in Mena and VASP, however, distinct cardiac roles of the proteins remain speculative. In the present study, we analyzed the physiological functions of Mena and VASP in the heart and also investigated the role of the proteins in the organization of cytoplasmic actin networks.
RESULTS: We generated a mouse model, which simultaneously lacks Mena and VASP in the heart. Mena/VASP double-deficiency induced dilated cardiomyopathy and conduction abnormalities. In wild-type mice, Mena and VASP specifically interacted with a distinct αII-Spectrin splice variant (SH3i), which is in cardiomyocytes exclusively localized at Z- and intercalated discs. At Z- and intercalated discs, Mena and β-actin localized to the edges of the sarcomeres, where the thin filaments are anchored. In Mena/VASP double-deficient mice, β-actin networks were disrupted and the integrity of Z- and intercalated discs was markedly impaired.
CONCLUSIONS: Together, our data suggest that Mena, VASP, and αII-Spectrin assemble cardiac multi-protein complexes, which regulate cytoplasmic actin networks. Conversely, Mena/VASP deficiency results in disrupted β-actin assembly, Z- and intercalated disc malformation, and induces dilated cardiomyopathy and conduction abnormalities.
Background: The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7 + 3 induction regimen consisting of continuous infusion cytarabine plus daunorubicin (DA).
Patients and methods: Patients with newly diagnosed AML >60 years were randomized to receive either intermediate-dose cytarabine (1000 mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m2 days 1–3) (IMA) or standard induction therapy with cytarabine (100 mg/m2 continuously days 1–7) plus daunorubicin (45 mg/m2 days 3–5) (DA). Patients in complete remission after DA received intermediate-dose cytarabine plus amsacrine as consolidation treatment, whereas patients after IMA were consolidated with standard-dose cytarabine plus mitoxantrone.
Results: Between February 2005 and October 2009, 485 patients were randomized; 241 for treatment arm DA and 244 for IMA; 76% of patients were >65 years. The complete response rate after DA was 39% [95% confidence interval (95% CI): 33–45] versus 55% (95% CI: 49–61) after IMA (odds ratio 1.89, P = 0.001). The 6-week early-death rate was 14% in both arms. Relapse-free survival curves were superimposable in the first year, but separated afterwards, resulting in 3-year relapse-free survival rates of 29% versus 14% in the DA versus IMA arms, respectively (P = 0.042). The median overall survival was 10 months in both arms (P = 0.513).
Conclusion: The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients. This did not translate into a survival advantage, most likely due to differences in consolidation treatment. Thus, effective consolidation strategies need to be further explored. In combination with an effective consolidation strategy, the use of intermediate-dose cytarabine in induction may improve curative treatment for elderly AML patients.
Objectives: Multidrug-resistant organisms (MDRO) are considered an emerging threat worldwide. Data covering the clinical impact of MDRO colonization in patients with solid malignancies, however, is widely missing. We sought to determine the impact of MDRO colonization in patients who have been diagnosed with Non-small cell lung cancer (NSCLC) who are at known high-risk for invasive infections.
Materials and methods: Patients who were screened for MDRO colonization within a 90-day period after NSCLC diagnosis of all stages were included in this single-center retrospective study.
Results: Two hundred and ninety-five patients were included of whom 24 patients (8.1%) were screened positive for MDRO colonization (MDROpos) at first diagnosis. Enterobacterales were by far the most frequent MDRO detected with a proportion of 79.2% (19/24). MDRO colonization was present across all disease stages and more present in patients with concomitant diabetes mellitus. Median overall survival was significantly inferior in the MDROpos study group with a median OS of 7.8 months (95% CI, 0.0–19.9 months) compared to a median OS of 23.9 months (95% CI, 17.6–30.1 months) in the MDROneg group in univariate (p = 0.036) and multivariate analysis (P = 0.02). Exploratory analyses suggest a higher rate of non-cancer-related-mortality in MDROpos patients compared to MDROneg patients (p = 0.002) with an increased rate of fatal infections in MDROpos patients (p = 0.0002).
Conclusions: MDRO colonization is an independent risk factor for inferior OS in patients diagnosed with NSCLC due to a higher rate of fatal infections. Empirical antibiotic treatment approaches should cover formerly detected MDR commensals in cases of (suspected) invasive infections.
INTRODUCTION: Older patients with acute myeloid leukemia (AML) experience short survival despite intensive chemotherapy. Azacitidine has promising activity in patients with low proliferating AML. The aim of this dose-finding part of this trial was to evaluate feasibility and safety of azacitidine combined with a cytarabine- and daunorubicin-based chemotherapy in older patients with AML.
TRIAL DESIGN: Prospective, randomised, open, phase II trial with parallel group design and fixed sample size.
PATIENTS AND METHODS: Patients aged 61 years or older, with untreated acute myeloid leukemia with a leukocyte count of <20,000/µl at the time of study entry and adequate organ function were eligible. Patients were randomised to receive azacitidine either 37.5 (dose level 1) or 75 mg/sqm (dose level 2) for five days before each cycle of induction (7+3 cytarabine plus daunorubicine) and consolidation (intermediate-dose cytarabine) therapy. Dose-limiting toxicity was the primary endpoint.
RESULTS: Six patients each were randomised into each dose level and evaluable for analysis. No dose-limiting toxicity occurred in either dose level. Nine serious adverse events occurred in five patients (three in the 37.5 mg, two in the 75 mg arm) with two fatal outcomes. Two patients at the 37.5 mg/sqm dose level and four patients at the 75 mg/sqm level achieved a complete remission after induction therapy. Median overall survival was 266 days and median event-free survival 215 days after a median follow up of 616 days.
CONCLUSIONS: The combination of azacitidine 75 mg/sqm with standard induction therapy is feasible in older patients with AML and was selected as an investigational arm in the randomised controlled part of this phase-II study, which is currently halted due to an increased cardiac toxicity observed in the experimental arm.
Previous studies in developing Xenopus and zebrafish reported that the phosphate transporter slc20a1a is expressed in pronephric kidneys. The recent identification of SLC20A1 as a monoallelic candidate gene for cloacal exstrophy further suggests its involvement in the urinary tract and urorectal development. However, little is known of the functional role of SLC20A1 in urinary tract development. Here, we investigated this using morpholino oligonucleotide knockdown of the zebrafish ortholog slc20a1a. This caused kidney cysts and malformations of the cloaca. Moreover, in morphants we demonstrated dysfunctional voiding and hindgut opening defects mimicking imperforate anus in human cloacal exstrophy. Furthermore, we performed immunohistochemistry of an unaffected 6-week-old human embryo and detected SLC20A1 in the urinary tract and the abdominal midline, structures implicated in the pathogenesis of cloacal exstrophy. Additionally, we resequenced SLC20A1 in 690 individuals with bladder exstrophy-epispadias complex (BEEC) including 84 individuals with cloacal exstrophy. We identified two additional monoallelic de novo variants. One was identified in a case-parent trio with classic bladder exstrophy, and one additional novel de novo variant was detected in an affected mother who transmitted this variant to her affected son. To study the potential cellular impact of SLC20A1 variants, we expressed them in HEK293 cells. Here, phosphate transport was not compromised, suggesting that it is not a disease mechanism. However, there was a tendency for lower levels of cleaved caspase-3, perhaps implicating apoptosis pathways in the disease. Our results suggest SLC20A1 is involved in urinary tract and urorectal development and implicate SLC20A1 as a disease-gene for BEEC.
Recombinase-mediated cassette exchange (RMCE) exploits the possibility to unidirectionally exchange any genetic material flanked by heterotypic recombinase recognition sites (RRS) with target sites in the genome. Due to a limited number of available pre-fabricated target sites, RMCE in mouse embryonic stem (ES) cells has not been tapped to its full potential to date. Here, we introduce a universal system, which allows the targeted insertion of any given transcriptional unit into 85 742 previously annotated retroviral conditional gene trap insertions, representing 7013 independent genes in mouse ES cells, by RMCE. This system can be used to express any given cDNA under the control of endogenous trapped promoters in vivo, as well as for the generation of transposon ‘launch pads’ for chromosomal region-specific ‘Sleeping Beauty’ insertional mutagenesis. Moreover, transcription of the gene-of-interest is only activated upon Cre-recombinase activity, a feature that adds conditionality to this expression system, which is demonstrated in vivo. The use of the RMCE system presented in this work requires one single-cloning step followed by one overnight gateway clonase reaction and subsequent cassette exchange in ES cells with efficiencies of 40% in average.